Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 232

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 232
---
 — |     |        | — |     |                | — |     |              | — |     |       | 470,000 |

Outstanding Equity Awards at 2023 Fiscal Year-End

As of December 31, 2024,
Dr. Hwang did not hold any outstanding equity awards with respect to Profusa.

<div align='center'>136</div>

Additional Narrative Disclosure

Severance Arrangements

Profusa generally executes
an offer of employment before an executive joins Profusa. This offer describes the basic terms of the executive’s employment, including
his or her start date, starting salary, annual incentive target (if any) and equity awards. Profusa does not maintain a general severance
policy. However, Dr. Hwang’s offer letter, dated January 1, 2013, provides that, upon a termination of employment by Profusa
without cause, Profusa will pay him six months’ base salary plus a pro-rata portion of any earned bonus payment (in a
lump sum payment), as well as pay his monthly COBRA premiums for up to six months, subject to Dr. Hwang’s execution of
a release of claims in favor of Profusa.

401(k) Plan

Profusa maintains a qualified
401(k) savings plan which allows participants to defer a portion of their compensation to the 401(k) savings plan on a before-tax and
after-tax basis. Profusa provides discretionary profit sharing contributions on behalf of its eligible participants. Profusa did
not make any profit sharing contributions in 2024.

Director Compensation

Profusa’s historical
director compensation program has consisted of equity awards. However, in 2024, Profusa did not grant any equity awards to its non-employee directors
and did not pay any cash director fees or other compensation to its non-employee directors. As of December 31, 2024, the non-employee directors
held outstanding options to purchase Profusa shares as follows: Joan Braddi — 80,000 shares. As Profusa’s Chief
Executive Officer, Dr. Hwang does not receive any additional compensation for his service on the Profusa board of directors. Please
see the Summary Compensation Table for the compensation paid or awarded to Dr. Hwang in 2024.

Granting of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

We do not grant equity
awards in anticipation of the release of material nonpublic information that is likely to